Uniqeness in fighting cancer
Avexxin Oncology AS is a biotech company in the Coegin Pharma Group. Our drug candidate AVX420 and its analogues have shown very promising data in preclinical triple negative breast cancer and leukemia.
About
AVX420 is a second-generation small molecule in the AVX family of potent and selective cPLA2α inhibitors and belongs to a chemical class of thiazolyl ketone analogues.
AVX420 inhibits cPLA2α resulting in significantly reduced levels of arachidonic acid, resulting in a pronounced effect on tumor growth inducing programmed cell death, anti-tumor inflammation, inhibition of angiogenesis, and anti-tumor proliferation.
Background
The global therapeutics market for cancer drugs is 166 billion USD, consisting of mix of old and newer drugs. The world’s largest cancer drug is MSD’s Keytruda® (pembrolizumab) which is indicated for several cancers and has an annual turnover of 17 billion USD.
Despite available drugs like chemotherapy and immunotherapy, a large unmet need persist for new cancer treatments that are both efficacious and safe.
The global therapeutics market for cancer drugs is 166 billion USD, consisting of mix of old and newer drugs.
Exit strategy
If the phase 1 trial reaches positive safety outcomes and signs of efficacy, Avexxin Oncology AS believe that a significant value of the asset will be in scope and we may aim for an early and attractive exit.
Series A funding and preclinical licensing deals in similar cases
Series A fundings in Europe for pre-clinical oncology companies/assets (blood and breast cancer) since 1. January 2018 has an average value of 27 mUSD. The most resent deal value of top small molecule licensing deals in breast cancer and leukemia had an average deal size of 589 mUSD.
Management
John R. Zibert
Chief Executive Officer
Erlend P. Skagseth
Board Member
Thoas Fioretos
Board Member